Naslov
Antibiotic use in 2003 in Europe

Autori
Ferech, M ; Coenen ; S, Hendrickx, E ; Dvorakova, K ; Goossens, H

Kolaboracija
ESAC project group

Izvornik
Clinical microbiology and infection (1198-743X) 11 (2005), S2; 9-9

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
Antibiotic use ; Europe

Sažetak
Objectives: ESAC, European Surveillance of Antimicrobial Consumption, granted by DG/SANCO of the European Commission, is an international network of surveillance systems, aiming to collect comparable and reliable data on antibiotic consumption in Europe. Thirty-four countries have joined the second phase of the ESAC project (2004– 2007), including all 25 EU countries and 4 current applicant countries. Methods: Outpatient and hospital antibiotic use for 2003 were collected, using the ATC/DDD methodology, version 2004. Results were expressed as DDD per 1000 inhabitants per day (DID). Detailed information on the sources of antibiotic use data can be found at the ESAC website (www.ua.ac.be/ESAC). Of the 34 participating countries 21, 19 and 2 were able to deliver outpatient, hospital and total data, resp., for 2003. In view of the expected change of DDD for parenteral co-amoxicillin, a pilot study on the pattern of consumption of antibiotics with multiple DDDs was conducted, based on data subdivided by route of administration. Results: Outpatient antibiotic use varied with a factor of 3.2 between the countries with the lowest and highest consumption, c.q. still the Netherlands (9.8 DID) and for the first time Greece (31.4 DID). Consumption in France decreased by 7.1% the year after their first national campaign. A similar reduction was seen in Belgium ()7.6%) after the first Belgian campaign. Hospital antibiotic use ranged between 1.4 DID in Norway and 3.6 DID in France. Nine substances with multiple DDDs were identified within the J01 ATC group: amoxicillin and enzyme inhibitor, cefuroxime, ciprofloxacin, clarithromycin, clindamycin, fosfomycin are available in oral and parenteral form, tobramycin in inhalatory and parenteral form, while DDDs for erythromycin and methenamine differ according to their chemical salts. Specifically consumption of parenteral co- amoxicillin was substantial in 4 out of 10 countries, which were able to deliver detailed data. Conclusion: ESAC data underpin the success of two national campaigns on antibiotic prescribing (Belgium and France). An introduction or change of DDD for a specific form of any antibiotic can substantially influence the profile of antibiotic consumption in some countries. Thus the ESAC data collection protocol shall be adjusted to allow us to control for these changes retrospectively, by collecting data at a product presentation level.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA